Welcome to our dedicated page for Ovid Therapeutics SEC filings (Ticker: OVID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ovid Therapeutics Inc. filings document a Nasdaq-listed biopharmaceutical company focused on small-molecule medicines for CNS disorders involving neuronal hyperexcitability. Its regulatory record includes 8-K disclosures for clinical program updates, operating and financial results, leadership and compensation arrangements, Nasdaq compliance, and capital-structure events involving common stock, preferred stock, warrants and pre-funded warrants.
Proxy statements disclose board and executive governance, equity compensation, shareholder meeting proposals, authorized-share matters, and stockholder votes required under Nasdaq rules for securities issuances. The filings also record material agreements, risk and governance subjects, and exhibits related to the company’s OV350, OV4071 and OV329 development programs.
Ovid Therapeutics Inc. reported a net loss of $17.0 million for the quarter ended March 31, 2026, wider than the $10.2 million loss a year earlier, as it increased investment in its epilepsy and CNS pipeline. Revenue was minimal, with no license or royalty income recognized this quarter versus $0.1 million in the prior-year period.
Research and development expenses rose to $11.2 million from $6.7 million, mainly driven by higher spending on OV329, the KCC2 library and OV4071. The company strengthened its balance sheet through an October 2025 private placement, warrant exercises, ATM sales and a March 2026 private placement, ending the quarter with $165.6 million in cash, cash equivalents and marketable securities and working capital of $144.4 million. Management believes this liquidity will fund operations for at least 12 months while Ovid advances multiple small-molecule programs for drug-resistant seizures and other brain disorders.
Ovid Therapeutics reported first quarter 2026 results and detailed progress across its neurology pipeline. The company ended March 31, 2026 with cash, cash equivalents and marketable securities of $165.6 million, not including an additional $27.3 million from April warrant exercises, and expects this cash to fund operations into 2029.
Ovid raised $60.0 million in gross proceeds from a March 2026 PIPE financing and received $53.9 million in gross proceeds from the full exercise of Series A warrants issued in an October 2025 private placement. In the quarter, research and development spending rose as OV329 and OV4071 advanced, leading to a net loss of $17.0 million, or $0.12 per share.
Clinically, OV329 showed favorable safety, tolerability and pharmacokinetics up to 9 mg, supporting planned Phase 2 studies in treatment-resistant focal onset seizures, with additional programs planned in tuberous sclerosis complex seizures and infantile spasms. Ovid also dosed the first healthy volunteer in a Phase 1 study of OV4071, its first oral KCC2 direct activator, and outlined broader KCC2 portfolio plans in multiple CNS disorders.
Ovid Therapeutics Inc. has released its 2026 proxy statement for a fully virtual annual meeting on June 10, 2026 at 10:30 a.m. Eastern Time. Stockholders of record as of April 15, 2026, holding 173,037,131 common shares in total, may vote.
Investors are asked to elect one Class III director (Jeremy M. Levin), approve on an advisory basis the compensation of named executive officers, and ratify KPMG LLP as independent auditor for 2026. The proxy describes a classified Board structure, independent Board committees, executive and director pay, and robust governance policies, including an insider trading policy, clawback policy and prohibitions on hedging and pledging. Voting can be completed online, by phone, by mail or during the virtual meeting using a 16-digit control number.
Ovid Therapeutics is registering for resale 29,856,031 shares of common stock originally issued in a March 2026 private placement, including 10,701,710 shares issuable upon exercise of Pre-Funded Warrants.
The registration covers resale by the private placement investors and their permitted transferees; Ovid will not receive proceeds from those resale transactions, although it will receive nominal proceeds if Pre-Funded Warrants are exercised for cash. The percentages shown in the selling-stockholder table use 173,037,131 shares outstanding as of April 17, 2026.
Ovid Therapeutics Inc. registered 29,856,031 shares of common stock for resale by selling stockholders pursuant to a March 17, 2026 private placement. The resale covers 19,154,321 issued shares and 10,701,710 shares issuable upon exercise of pre-funded warrants.
The registration is being filed to satisfy contractual registration rights and does not require the selling stockholders to sell shares. Ovid will not receive proceeds from resales by the selling stockholders; the company received approximately $60.0 million gross from the Private Placement and would receive nominal proceeds only upon any cash exercise of the pre-funded warrants. Common stock trades on Nasdaq under OVID; last reported sale price was $2.91 on April 17, 2026.
Ovid Therapeutics Inc. reported that its Series A Warrants issued in an October 2025 private placement expired on April 17, 2026. Holders elected to exercise warrants into 33,597,860 common shares at $1.40 per share and 4,883,464 pre-funded warrants at $1.399 per warrant.
These exercises covered most of the 38,481,325 common shares underlying the Series A Warrants and generated approximately $53.9 million in gross cash proceeds for the company.
PAPADOPOULOS STELIOS reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics director Stelios Papadopoulos received a stock-based compensation award in the form of restricted stock units. The grant covers 17,578 shares of common stock valued at $2.56 per share, replacing a $45,000 annual cash retainer. The RSUs vest 25% at grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, contingent on continued board service. After this award, he holds 217,578 common shares directly.
Friedman Bart reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. reported that director Bart Friedman received a grant of 8,789 shares of Common Stock as a restricted stock unit (RSU) award, valued at $22,500 based on a reference price of $2.56 per share.
The RSU award was issued under Ovid’s Non-Employee Director Compensation Policy in lieu of 50% of his annual cash retainer for Board service. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026, and December 31, 2026, conditioned on his continuous service.